中央明确明年优化药品集中采购，可以从哪些方面入手？

Core Viewpoint - The article discusses the key tasks determined at the Central Economic Work Conference held on December 10-11, focusing on optimizing drug centralized procurement and deepening medical insurance payment reform [3]. Group 1: Drug Centralized Procurement - Since the launch of the "4+7" centralized procurement pilot by the National Healthcare Security Administration in November 2018, eleven batches of drug procurement have been conducted, successfully procuring 490 types of drugs [3]. - The goals of drug centralized procurement include reducing the economic burden on insured individuals by cutting out intermediaries and improving the efficiency of medical insurance funds, while also pushing companies towards innovation [3]. Group 2: Recent Developments in Procurement - The results of the eleventh batch of national drug centralized procurement were announced on October 27, 2025, including 55 types of commonly used drugs across various fields such as anti-infection, anti-allergy, anti-tumor, and others [4]. - The eleventh batch aims to achieve the expected goals of "stabilizing clinical use, ensuring quality, countering internal competition, and preventing collusion" [5]. Group 3: Future Considerations - There is significant attention on how to further counter internal competition in future drug procurements, with industry insiders expressing concerns about the lack of a minimum bidding price in the current procurement rules [6]. - Suggestions for optimizing procurement rules include potentially setting a "bottom price" for bids and exploring the separation of medical insurance payment standards from drug prices, ensuring that off-list drugs remain available while reducing their prices [6].